OMER 250117 17.00C (OMER250117C17000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

OMER250117C17000

Watchlist

0.05
-0.10-66.67%

15min DelayClose Dec 31 16:00 ET

0.07High0.05Low

Intraday

5D
Daily

News

When Can We Expect A Profit From Omeros Corporation (NASDAQ:OMER)?
Yahoo FinanceDec 27, 2024 06:35 ET
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
BenzingaDec 23, 2024 10:36 ET
D. Boral Capital Initiates Omeros(OMER.US) With Buy Rating, Announces Target Price $36
Moomoo NewsDec 23, 2024 07:33 ET · Ratings
Omeros Initiated at Buy by D. Boral Capital
Dow JonesDec 23, 2024 07:19 ET · Ratings
Express News | D. Boral Capital Initiates Coverage On Omeros With Buy Rating, Announces Price Target of $36
BenzingaDec 23, 2024 07:06 ET
Needham Maintains Omeros(OMER.US) With Hold Rating
Moomoo NewsDec 20, 2024 13:43 ET · Ratings

Comments

Tedchua95

Dec 19, 2024 09:42

$Omeros (OMER.US)$ Clean movement.

Jaguar8

Dec 19, 2024 08:41

NEWS

$Omeros (OMER.US)$
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...

Trytosaveabit

Dec 19, 2024 08:35

News

$Omeros (OMER.US)$ Omeros' Narsoplimab Meets Its Pivotal Trial Primary Endpoint! Omeros Corp: To Resubmit a Bla to FDA for Narsoplimab

Shootingstars

Dec 19, 2024 08:27

$Omeros (OMER.US)$ Straight to 15

Shootingstars

Nov 22, 2024 13:49

$Omeros (OMER.US)$ Sky rocket